Target intelligence / Profile preview

p53 upregulated regulator of p53 levels (PURPL)

Target
PURPL
Molecular classification
Long intergenic non-coding RNA (lincRNA), long non-coding RNA (lncRNA), non-coding RNA
01

Overview

PURPL (p53 upregulated regulator of p53 levels) is a human long intergenic non-coding RNA (lincRNA) induced by p53 following DNA damage and is encoded by the genomic locus LOC643401/LINC01021/RP11-46C20.1. PURPL is nuclear-localized and forms a negative feedback loop with p53: it is transcriptionally activated by p53 and, in turn, suppresses basal p53 protein levels. Mechanistically, PURPL sequesters the protein MYBBP1A (which stabilizes and activates p53) via an adaptor RNA-binding protein, HuR, thereby inhibiting MYBBP1A's binding to p53 and limiting p53 stabilization[1]. Knockout or knockdown of PURPL increases p53 levels and impairs proliferation and tumorigenicity of colorectal cancer cells both in vitro and in vivo[1][2]. High expression of PURPL is associated with cancer cell survival and resistance to chemotherapeutic stress. PURPL does not encode a protein and is not a canonical drug target such as a receptor, enzyme, or transporter, but disrupts cancer cell homeostasis via RNA-mediated modulation of the p53 pathway[1][3].

Other names
LOC643401LINC01021RP11-46C20.1long intergenic non-protein coding RNA 1021
02

Mechanism of action

Not applicable; not a classical druggable protein target. PURPL negatively regulates p53 protein levels by sequestering MYBBP1A via an RNA-binding adaptor (HuR), thereby inhibiting p53 stabilization[1][2].

03

Biological functions

Regulation of basal p53 levelsnegative regulation of p53-mediated gene expressionmaintenance of cell proliferation and survival in colorectal and gastric cancer cellsparticipation in DNA damage response
04

Disease associations

Cancer (including colorectal cancer, gastric cancer)
05

Safety considerations

Therapeutic targeting could result in dysregulated p53 activation, potentially increasing apoptosis and affecting tissue homeostasisfurther preclinical safety studies would be required[1]
06

Biomarkers

Potential biomarker for colorectal and gastric cancer progressionhigh PURPL expression is associated with tumorigenicity and chemoresistance[1][3]

Beyond the preview

Go deeper on p53 upregulated regulator of p53 levels (PURPL).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on p53 upregulated regulator of p53 levels (PURPL).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call